Find Research outputs

Search results

• Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome

  Chien, K. S., Kim, K., Nogueras-Gonzalez, G. M., Borthakur, G., Naqvi, K., Daver, N. G., Montalban-Bravo, G., Cortes, J. E., DiNardo, C. D., Jabbour, E., Alvarado, Y., Andreeff, M., Bose, P., Jain, N., Kadia, T. M., Huang, X., Sheppard, K. B., Klingner-Winton, C., Pierce, S. A., Dong, X. Q. & 3 others, Soltysiak, K. A., Kantarjian, H. M. & Garcia-Manero, G., Nov 2021, In: British Journal of Haematology. 195, 3, p. 378-387 10 p.

  Research output: Contribution to journal › Article › peer-review
  4 Scopus citations

• Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer

  Mott, F. E., Cable, C. T. & Sharma, N., Nov 2003, In: Clinical Lung Cancer. 5, 3, p. 174-176 3 p.

  Research output: Contribution to journal › Article › peer-review
  8 Scopus citations

• Phase II study of alemtuzumab in chronic lymphoproliferative disorders

  Ferrajoli, A., O'Brien, S. M., Cortes, J. E., Giles, F. J., Thomas, D. A., Faderl, S., Kurzrock, R., Lerner, S., Kontoyiannis, D. P. & Keating, M. J., Aug 15 2003, In: Cancer. 98, 4, p. 773-778 6 p.

  Research output: Contribution to journal › Article › peer-review
  122 Scopus citations

• Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma

  Sharma, K., Janik, J. E., O'Mahony, D., Stewart, D., Pittaluga, S., Stetler-Stevenson, M., Jaffe, E. S., Raffeld, M., Fleisher, T. A., Lee, C. C., Steinberg, S. M., Waldmann, T. A. & Morris, J. C., Jan 1 2017, In: Clinical Cancer Research. 23, 1, p. 35-42 8 p.

  Research output: Contribution to journal › Article › peer-review
  23 Scopus citations

• Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome

  Chacar, C., Jabbour, E., Ravandi, F., Borthakur, G., Kadia, T., Estrov, Z., Rios, M. B., Cortes, J. & Kantarjian, H., Jun 2012, In: Clinical Lymphoma, Myeloma and Leukemia. 12, 3, p. 197-200 4 p.

  Research output: Contribution to journal › Article › peer-review
  3 Scopus citations

• Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study

  Cortes, J. E., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D. W., Pane, F., Pasquini, R., Goldberg, S. L., Kalaycio, M., Moiraghi, B., Rowe, J. M., Tothova, E., De Souza, C., Rudoltz, M., Yu, R., Krahnke, T., Kantarjian, H. M., Radich, J. P. & Hughes, T. P., Jan 20 2010, In: Journal of Clinical Oncology. 28, 3, p. 424-430 7 p.

  Research output: Contribution to journal › Article › peer-review
  219 Scopus citations

• Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis

  Sasaki, K., Gotlib, J. R., Mesa, R. A., Newberry, K. J., Ravandi, F., Cortes, J. E., Kelly, P., Kutok, J. L., Kantarjian, H. M. & Verstovsek, S., Jul 1 2015, In: Leukemia and Lymphoma. 56, 7, p. 2092-2097 6 p.

  Research output: Contribution to journal › Article › peer-review
  45 Scopus citations

• Phase II clinical trial of gefitinib for the treatment of chemonaïve patients with advanced non-small cell lung cancer with poor performance status

  Karim, N. A., Musaad, S., Zarzour, A., Patil, S. & Jazieh, A. R., Nov 25 2014, In: Clinical Medicine Insights: Oncology. 8, p. 121-128 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  4 Scopus citations

• Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability

  Berry, J. D., Paganoni, S., Atassi, N., Macklin, E. A., Goyal, N., Rivner, M., Simpson, E., Appel, S., Grasso, D. L., Mejia, N. I., Mateen, F., Gill, A., Vieira, F., Tassinari, V. & Perrin, S., Dec 2017, In: Muscle and Nerve. 56, 6, p. 1077-1084 8 p.

  Research output: Contribution to journal › Article › peer-review
  23 Scopus citations

• Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine

  Badar, T., Cortes, J., Borthakur, G., O'Brien, S., Wierda, W., Garcia-Manero, G., Ferrajoli, A., Kadia, T., Poku, R., Kantarjian, H. & Mattiuzzi, G., Jan 15 2015, In: BioMed Research International. 2015, 497597.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  6 Scopus citations

• Phase II, multicenter, randomized trial of CPX-351 (cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

  Cortes, J. E., Goldberg, S. L., Feldman, E. J., Rizzeri, D. A., Hogge, D. E., Larson, M., Pigneux, A., Recher, C., Schiller, G., Warzocha, K., Kantarjian, H., Louie, A. C. & Kolitz, J. E., Jan 15 2015, In: Cancer. 121, 2, p. 234-242 9 p.

  Research output: Contribution to journal › Article › peer-review
  124 Scopus citations

• Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

  Verstovsek, S., Tam, C. S., Wadleigh, M., Sokol, L., Smith, C. C., Bui, L. A., Song, C., Clary, D. O., Olszynski, P., Cortes, J., Kantarjian, H. & Shah, N. P., Mar 2014, In: Leukemia Research. 38, 3, p. 316-322 7 p.

  Research output: Contribution to journal › Article › peer-review
  41 Scopus citations

• Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-α-2a with and without cytarabine in patients with chronic myelogenous leukemia

  Talpaz, M., Rakhit, A., Rittweger, K., O'Brien, S., Cortes, J., Fettner, S., Hooftman, L. & Kantarjian, H., Sep 1 2005, In: Clinical Cancer Research. 11, 17, p. 6247-6255 9 p.

  Research output: Contribution to journal › Article › peer-review
  30 Scopus citations

• Phase I clinical trial of the chimeric monoclonal antibody (c30.6) in patients with metastatic colorectal cancer

  Ward, R. L., Packham, D., Smythe, A. M., Murray, J., Anderson-Stewart, P., Kitchen, N., Muirhead, R., Phillips, P., Gray, P., Bigg-Wither, G., Prabakaran, K., Freund, J., Fullham, M., Rule, M., Dalley, D., Meagher, A., Hawkins, N. J. & Smith, G. M., Dec 2000, In: Clinical Cancer Research. 6, 12, p. 4674-4683 10 p.

  Research output: Contribution to journal › Article › peer-review
  6 Scopus citations

• Phase I clinical trial of donor t-helper type 2 cells after immunoablative, reduced intensity allogeneic PBSC transplant

  Fowler, D., Hou, J., Foley, J., Hakim, F., Odom, J., Castro, K., Carter, C., Read, E., Gea-Banacloche, J., Kasten-Sportes, C., Kwak, L., Wilson, W., Levine, B., June, C., Gress, R. & Bishop, M., Jan 1 2002, In: Cytotherapy. 4, 5, p. 429-430 2 p.

  Research output: Contribution to journal › Article › peer-review
  18 Scopus citations

• Phase I Clinical Trial of Costimulated, IL-4 Polarized Donor CD4⁺ T Cells as Augmentation of Allogeneic Hematopoietic Cell Transplantation

  Fowler, D. H., Odom, J., Steinberg, S. M., Chow, C. K., Foley, J., Kogan, Y., Hou, J., Gea-Banacloche, J., Sportes, C., Pavletic, S., Leitman, S., Read, E. J., Carter, C., Kolstad, A., Fox, R., Beatty, G. L., Vonderheide, R. H., Levine, B. L., June, C. H., Gress, R. E. & 1 others, Bishop, M. R., Nov 2006, In: Biology of Blood and Marrow Transplantation. 12, 11, p. 1150-1160 11 p.

  Research output: Contribution to journal › Article › peer-review
  54 Scopus citations

• Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers

  Kantarjian, H. M., Gandhi, V., Kozuch, P., Faderl, S., Giles, F., Cortes, J., O'Brien, S., Ibrahim, N., Khuri, F., Du, M., Rios, M. B., Jeha, S., McLaughlin, P., Plunkett, W. & Keating, M., Mar 15 2003, In: Journal of Clinical Oncology. 21, 6, p. 1167-1173 7 p.

  Research output: Contribution to journal › Article › peer-review
  176 Scopus citations

• Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

  Kantarjian, H., Garcia-Manero, G., O'Brien, S., Faderl, S., Ravandi, F., Westwood, R., Green, S. R., Chiao, J. H., Boone, P. A., Cortes, J. & Plunkett, W., Jan 10 2010, In: Journal of Clinical Oncology. 28, 2, p. 285-291 7 p.

  Research output: Contribution to journal › Article › peer-review
  67 Scopus citations

• Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?

  Cassel, J. B., Del Fabbro, E., Arkenau, T., Higginson, I. J., Hurst, S., Jansen, L. A., Poklepovic, A., Rid, A., Rodón, J., Strasser, F. & Miller, F. G., Sep 1 2016, In: Journal of Pain and Symptom Management. 52, 3, p. 437-445 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  18 Scopus citations

• Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

  Stone, R. M., Fischer, T., Paquette, R., Schiller, G., Schiffer, C. A., Ehninger, G., Cortes, J., Kantarjian, H. M., Deangelo, D. J., Huntsman-Labed, A., Dutreix, C., Del Corral, A. & Giles, F., Sep 2012, In: Leukemia. 26, 9, p. 2061-2068 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  205 Scopus citations

• Phase ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS

  Savona, M. R., Pollyea, D. A., Stock, W., Oehler, V. G., Schroeder, M. A., Lancet, J., McCloskey, J., Kantarjian, H. M., Ma, W. W., Naveed Shaik, M., Douglas Laird, A., Zeremski, M., O'Connell, A., Chan, G. & Cortes, J. E., May 15 2018, In: Clinical Cancer Research. 24, 10, p. 2294-2303 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  67 Scopus citations

• Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

  Nayak-Kapoor, A., Hao, Z., Sadek, R., Dobbins, R., Marshall, L., Vahanian, N. N., Jay Ramsey, W., Kennedy, E., Mautino, M. R., Link, C. J., Lin, R. S., Royer-Joo, S., Liang, X., Salphati, L., Morrissey, K. M., Mahrus, S., McCall, B., Pirzkall, A., Munn, D. H., Janik, J. E. & 1 others, Khleif, S. N., Jun 20 2018, In: Journal for ImmunoTherapy of Cancer. 6, 1, 61.

  Research output: Contribution to journal › Article › peer-review
  63 Scopus citations

• Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia

  Vey, N., Kantarjian, H. M., Tran, H., Beran, M., O'Brien, S., Bivins, C., Giles, F., Cortes, J., Cheson, B., Arbuck, S. & Estey, E., 1999, In: Annals of Oncology. 10, 5, p. 577-583 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  20 Scopus citations

• Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia

  Giles, F. J., Cortes, J. E., Thomas, D. A., Garcia-Manero, G., Faderl, S., Jeha, S., De Jager, R. L. & Kantarjian, H. M., 2002, In: Clinical Cancer Research. 8, 7, p. 2134-2141 8 p.

  Research output: Contribution to journal › Article › peer-review
  25 Scopus citations

• Phase I and Pharmacokinetic Study of a Low-Clearance, Unilamellar Liposomal Formulation of Lurtotecan, a Topoisomerase 1 Inhibitor, in Patients with Advanced Leukemia

  Giles, F. J., Tallman, M. S., Garcia-Manero, G., Cortes, J. E., Thomas, D. A., Wierda, W. G., Verstovsek, S., Hamilton, M., Barrett, E., Albitar, M. & Kantarjian, H. M., Apr 1 2004, In: Cancer. 100, 7, p. 1449-1458 10 p.

  Research output: Contribution to journal › Article › peer-review
  38 Scopus citations

• Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

  Giles, F. J., Fracasso, P. M., Kantarjian, H. M., Cortes, J. E., Brown, R. A., Verstovsek, S., Alvarado, Y., Thomas, D. A., Faderl, S., Garcia-Manero, G., Wright, L. P., Samson, T., Cahill, A., Lambert, P., Plunkett, W., Sznol, M., DiPersio, J. F. & Gandhi, V., Dec 1 2003, In: Leukemia Research. 27, 12, p. 1077-1083 7 p.

  Research output: Contribution to journal › Article › peer-review
  90 Scopus citations

• Phase i and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia

  Faderl, S., Balakrishnan, K., Thomas, D. A., Ravandi, F., Borthakur, G., Burger, J., Ferrajoli, A., Cortes, J., O'Brien, S., Kadia, T., Feliu, J., Plunkett, W., Gandhi, V. & Kantarjian, H. M., Jun 2014, In: Clinical Lymphoma, Myeloma and Leukemia. 14, 3, p. 231-238 8 p.

  Research output: Contribution to journal › Article › peer-review
  10 Scopus citations

• Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

  Strati, P., Kantarjian, H., Ravandi, F., Nazha, A., Borthakur, G., Daver, N., Kadia, T., Estrov, Z., Garcia-Manero, G., Konopleva, M., Rajkhowa, T., Durand, M., Andreeff, M., Levis, M. & Cortes, J., Apr 1 2015, In: American Journal of Hematology. 90, 4, p. 276-281 6 p.

  Research output: Contribution to journal › Article › peer-review
  112 Scopus citations

• Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes

  Salman, H. S., Tanaka, K. & Sparano, J. A., 2002, In: Clinical Breast Cancer. 2, 4, p. 299-303 5 p.

  Research output: Contribution to journal › Article › peer-review
  7 Scopus citations

• Phase I/II trial of 5-fluorouracil, leucovorin, zidovudine and dipyridamole for patients with metastatic colorectal cancer, renal cell carcinoma and malignant melanoma

  Sharfman, W. H., Urba, W. J., Smith, J. W., Janik, J. E., Curti, B. D., Gause, B. L., Holmlund, J. T., Steis, R. G., Beauchamp, A. E. & Longo, D. L., 1995, In: International journal of oncology. 6, 3, p. 579-583 5 p.

  Research output: Contribution to journal › Article › peer-review
  4 Scopus citations

• Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

  Konopleva, M., Thall, P. F., Yi, C. A., Borthakur, G., Coveler, A., Bueso-Ramos, C., Benito, J., Konoplev, S., Gu, Y., Ravandi, F., Jabbour, E., Faderl, S., Thomas, D., Cortes, J., Kadia, T., Kornblau, S., Daver, N., Pemmaraju, N., Nguyen, H. Q., Feliu, J. & 8 others, Lu, H., Wei, C., Wilson, W. R., Melink, T. J., Gutheil, J. C., Andreeff, M., Estey, E. H. & Kantarjian, H., Jul 6 2015, In: Haematologica. 100, 7, p. 927-934 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  61 Scopus citations

• Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy

  Quintás-Cardama, A., Kantarjian, H., Garcia-Manero, G., O'Brien, S., Faderl, S., Estrov, Z., Giles, F., Murgo, A., Ladie, N., Verstovsek, S. & Cortes, J., Jan 15 2007, In: Cancer. 109, 2, p. 248-255 8 p.

  Research output: Contribution to journal › Article › peer-review
  113 Scopus citations

• Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

  Maiti, A., Cortes, J. E., Brown, Y. D. & Kantarjian, H. M., Mar 4 2017, In: Leukemia and Lymphoma. 58, 3, p. 722-725 4 p.

  Research output: Contribution to journal › Letter › peer-review
  3 Scopus citations

• Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia

  Abaza, Y., Kantarjian, H., Alwash, Y., Borthakur, G., Champlin, R., Kadia, T., Garcia-Manero, G., Daver, N., Ravandi, F., Verstovsek, S., Burger, J., Estrov, Z., Ohanian, M., Lim, M., Pemmaraju, N., Jabbour, E. & Cortes, J., Nov 1 2020, In: American Journal of Hematology. 95, 11, p. 1288-1295 8 p.

  Research output: Contribution to journal › Article › peer-review
  12 Scopus citations

• Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

  Ravandi, F., Cortes, J. E., Jones, D., Faderl, S., Garcia-Manero, G., Konopleva, M. Y., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., Pierce, S. R., Brandt, M., Byrd, A., Bekele, B. N., Pratz, K., Luthra, R., Levis, M., Andreeff, M. & Kantarjian, H. M., Apr 10 2010, In: Journal of Clinical Oncology. 28, 11, p. 1856-1862 7 p.

  Research output: Contribution to journal › Article › peer-review
  306 Scopus citations

• Phase diagram of two-component dipolar fermions in one-dimensional optical lattices

  De Silva, T. N., May 3 2013, In: Physics Letters, Section A: General, Atomic and Solid State Physics. 377, 12, p. 871-877 7 p.

  Research output: Contribution to journal › Article › peer-review
  8 Scopus citations

• Phase diagram of strongly attractive p-orbital fermions on optical lattices

  De Silva, T. N., Oct 30 2015, In: Physics Letters, Section A: General, Atomic and Solid State Physics. 379, 42, p. 2715-2722 8 p., 23378.

  Research output: Contribution to journal › Article › peer-review

• Phase Changes in a Leucite‐Containing Dental Porcelain Frit

  Rodway Mackert, J., Butts, M. B., Morena, R. & Fairhurst, C. W., Apr 1986, In: Journal of the American Ceramic Society. 69, 4, p. C‐69-C‐72

  Research output: Contribution to journal › Article › peer-review
  38 Scopus citations

• Phase 3 study of quizartinib (AC220) monotherapy vs salvage chemotherapy (SC) in patients (pts) with FLT3-ITD+ acute myeloid leukemia (AML) refractory to or relapsed (R/R) after 1st-line treatment with or without hematopoietic stem cell transplant (HSCT) consolidation: the QuANTUM-R study

  Cortes, J., Gammon, G., Khaled, S., Martinelli, G., Kramer, A., Steffen, B., Hogge, D., Jonas, B. A., Dombret, H. & Perl, A., Oct 1 2016, In: Annals of Oncology. 27, p. vi327

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-Month median follow-up

  Kantarjian, H., Cortes, J., Kim, D. W., Dorlhiac-Llacer, P., Pasquini, R., DiPersio, J., Müller, M. C., Radich, J. P., Khoury, H. J., Khoroshko, N., Bradley-Garelik, M. B., Zhu, C. & Tallman, M. S., 2009, In: Blood. 113, 25, p. 6322-6329 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  148 Scopus citations

• Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

  Ravandi, F., Ritchie, E. K., Sayar, H., Lancet, J. E., Craig, M. D., Vey, N., Strickland, S. A., Schiller, G. J., Jabbour, E., Pigneux, A., Horst, H. A., Récher, C., Klimek, V. M., Cortes, J. E., Carella, A. M., Egyed, M., Krug, U., Fox, J. A., Craig, A. R., Ward, R. & 4 others, Smith, J. A., Acton, G., Kantarjian, H. M. & Stuart, R. K., Oct 31 2018, In: Haematologica. 103, 11, p. e514-e518

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  7 Scopus citations

• Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/ daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

  Lancet, J. E., Cortes, J. E., Hogge, D. E., Tallman, M. S., Kovacsovics, T. J., Damon, L. E., Komrokji, R., Solomon, S. R., Kolitz, J. E., Cooper, M., Yeager, A. M., Louie, A. C. & Feldman, E. J., May 22 2014, In: Blood. 123, 21, p. 3239-3246 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  249 Scopus citations

• Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

  Eghtedar, A., Verstovsek, S., Estrov, Z., Burger, J., Cortes, J., Bivins, C., Faderl, S., Ferrajoli, A., Borthakur, G., George, S., Scherle, P. A., Newton, R. C., Kantarjian, H. M. & Ravandi, F., May 17 2012, In: Blood. 119, 20, p. 4614-4618 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  156 Scopus citations

• Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

  Cortes, J., Digumarti, R., Parikh, P. M., Wetzler, M., Lipton, J. H., Hochhaus, A., Craig, A. R., Benichou, A. C., Nicolini, F. E. & Kantarjian, H. M., May 2013, In: American Journal of Hematology. 88, 5, p. 350-354 5 p.

  Research output: Contribution to journal › Article › peer-review
  51 Scopus citations

• Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

  Cortes, J., Lipton, J. H., Rea, D., Digumarti, R., Chuah, C., Nanda, N., Benichou, A. C., Craig, A. R., Michallet, M., Nicolini, F. E. & Kantarjian, H., Sep 27 2012, In: Blood. 120, 13, p. 2573-2580 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  112 Scopus citations

• Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission

  Abou Dalle, I., Kantarjian, H. M., Ravandi, F., Daver, N., Wang, X., Jabbour, E., Estrov, Z., DiNardo, C. D., Pemmaraju, N., Ferrajoli, A., Jain, N., Wang, S. A., Jammal, N., Borthakur, G., Naqvi, K., Pelletier, S., Pierce, S., Andreeff, M., Garcia-Manero, G., Cortes, J. E. & 1 others, Kadia, T. M., Jun 1 2021, In: Cancer. 127, 11, p. 1894-1900 7 p.

  Research output: Contribution to journal › Article › peer-review
  1 Scopus citations

• Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia

  Sasaki, K., Kantarjian, H., Wierda, W., Ravandi-Kashani, F., Jorgensen, J., Wang, S. A., Khoury, J., Daver, N., Burger, J., Di Nardo, C. D., Jain, N., Short, N. J., Estrov MD, Z., Konopleva MD, PhD, M., Ohanian DO, M., Garcia-Manero, G., Kadia, T., Alvarado-Valero, Y., Yilmaz, M., Pierce, S. & 5 others, Garris, R., Ingram, A., Cortes, J., OʼBrien, S. & Jabbour, E., Jul 1 2020, In: American Journal of Hematology. 95, 7, p. 734-739 6 p.

  Research output: Contribution to journal › Article › peer-review
  6 Scopus citations

• Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

  Santos, F. P. S., Kantarjian, H. M., Jain, N., Manshouri, T., Thomas, D. A., Garcia-Manero, G., Kennedy, D., Estrov, Z., Cortes, J. & Verstovsek, S., Feb 11 2010, In: Blood. 115, 6, p. 1131-1136 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  183 Scopus citations

• Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

  Ravandi, F., Alattar, M. L., Grunwald, M. R., Rudek, M. A., Rajkhowa, T., Richie, M. A., Pierce, S., Daver, N., Garcia-Manero, G., Faderl, S., Nazha, A., Konopleva, M., Borthakur, G., Burger, J., Kadia, T., Dellasala, S., Andreeff, M., Cortes, J., Kantarjian, H. & Levis, M., Jun 6 2013, In: Blood. 121, 23, p. 4655-4662 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  288 Scopus citations

• Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

  Cortes, J., Kantarjian, H., Ball, E. D., DiPersio, J., Kolitz, J. E., Fernandez, H. F., Goodman, M., Borthakur, G., Baer, M. R. & Wetzler, M., Jan 15 2012, In: Cancer. 118, 2, p. 418-427 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  23 Scopus citations